Q3 Earnings Forecast for Vor Biopharma Issued By Wedbush

Key Points

• Wedbush analysts have raised their Q3 2025 earnings estimates for Vor Biopharma from ($0.19) to ($0.03) per share, maintaining an "Outperform" rating on the stock.
• The consensus rating for Vor Biopharma is currently "Moderate Buy" with an average price target of $6.07, despite several analysts downgrading their ratings recently.
• Vor Biopharma's stock is trading at $1.98, showing a significant increase from its 12-month low of $0.13, with a market capitalization of approximately $250.75 million.

Vor Biopharma Inc. (NYSE:VOR - Free Report) - Equities researchers at Wedbush increased their Q3 2025 earnings per share estimates for shares of Vor Biopharma in a research note issued to investors on Wednesday, August 13th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($0.03) for the quarter, up from their prior estimate of ($0.19). Wedbush currently has a "Outperform" rating on the stock. The consensus estimate for Vor Biopharma's current full-year earnings is ($1.42) per share. Wedbush also issued estimates for Vor Biopharma's Q4 2025 earnings at ($0.03) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.03) EPS and FY2026 earnings at ($0.14) EPS.

A number of other research analysts have also recently issued reports on VOR. HC Wainwright reiterated a "buy" rating and issued a $3.00 target price on shares of Vor Biopharma in a research report on Thursday, August 14th. JMP Securities reaffirmed a "market perform" rating and set a $6.00 price target on shares of Vor Biopharma in a report on Friday, May 9th. Jones Trading downgraded shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Baird R W lowered shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Finally, Citizens Jmp cut shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 9th. Five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $6.07.

Vor Biopharma Price Performance

Shares of VOR stock traded up $0.1550 on Friday, hitting $2.2050. 5,087,781 shares of the company's stock were exchanged, compared to its average volume of 7,945,833. The company has a 50 day moving average of $1.66 and a 200 day moving average of $1.05. The stock has a market cap of $279.34 million, a P/E ratio of -1.34 and a beta of 2.06. Vor Biopharma has a 12 month low of $0.13 and a 12 month high of $3.29.

Institutional Trading of Vor Biopharma

Several large investors have recently modified their holdings of the stock. XTX Topco Ltd acquired a new position in shares of Vor Biopharma during the 4th quarter valued at $80,000. Lynx1 Capital Management LP acquired a new position in shares of Vor Biopharma during the fourth quarter valued at about $707,000. Northern Trust Corp boosted its position in shares of Vor Biopharma by 39.0% during the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company's stock worth $175,000 after purchasing an additional 44,252 shares in the last quarter. RA Capital Management L.P. boosted its position in shares of Vor Biopharma by 74.3% during the 4th quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company's stock worth $44,007,000 after purchasing an additional 16,897,159 shares in the last quarter. Finally, Trustees of Columbia University in the City of New York acquired a new stake in shares of Vor Biopharma in the 4th quarter valued at about $102,000. Institutional investors and hedge funds own 97.29% of the company's stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.